Pharmacokinetics of the Brimonidine Tartrate Posterior Segment Delivery System in Patients Undergoing Pars Plana Vitrectomy
Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the pharmacokinetics of brimonidine following a single intravitreal
administration of the 200 ug or 400 ug Brimonidine Tartrate Posterior Segment Drug Delivery
System in patients 2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy.